Phase III, open-label, long-term safety study of topical RT 001 [botulinum toxin A] for the treatment of lateral canthal lines

Trial Profile

Phase III, open-label, long-term safety study of topical RT 001 [botulinum toxin A] for the treatment of lateral canthal lines

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 May 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Facial-wrinkles
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 13 May 2015 According to a Revance Therapeutics media release, status changed from recruiting to active, no longer recruiting.
    • 26 May 2014 New trial record
    • 13 May 2014 Interim data is expected in 2015, according to a Revance Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top